NEONEOGENOMICS INC
Services-Testing Laboratories
- Revenue
- $727M
- 10% YoY
- Operating margin
- -15.9%
- 14% YoY
- EBITDA
- −$80M
- 51% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- $399M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear6% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear38% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $484M | $510M | $592M | $661M | $727M | 10% |
| Operating income | −$119M | −$158M | −$108M | −$92M | −$116M | 26% |
| Net income | −$8M | −$144M | −$88M | −$79M | −$108M | 37% |
| Operating cash flow | −$27M | −$66M | −$2M | $7M | $5M | 26% |
| Capex | $64M | $31M | $29M | $41M | $27M | 34% |
| Stock-based comp | $22M | $25M | $25M | $33M | $41M | 24% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 22 | 125 |
| FY2024 | — | — | 56 | 118 |
| FY2023 | — | — | 55 | 119 |
| FY2022 | — | — | 32 | 114 |
| FY2021 | — | — | 117 | 126 |